Abstract: The present disclosure related to methods to treat, prevent (e.g., suppress, inhibit or delay), or ameliorate the symptoms of a TLR-4 mediated disease or condition comprising administering an aptamer of the present disclosure to a subject in need thereof, alone or combination with other pharmacological and/or surgical interventions. In a particular aspect, the aptamers of the present disclosure are administered before, during, or after pharmacological and/or surgical interventions (e.g., thrombolysis such as thrombectomy) or any combination thereof, for the treatment of ischemic (e.g., myocardial infarction or ischemic stroke), hemorrhagic (e.g., hemorrhagic stroke or hemorrhagic transformation), or neurodegenerative (e.g., multiple sclerosis) diseases or conditions. The disclosure also provides specific doses and dosage regimes.

Abstract: The present disclosure related to methods to treat, prevent (e.g., suppress, inhibit or delay), or ameliorate the symptoms of ischemic stroke comprising administering an aptamer of the present disclosure to a subject in need thereof, alone or combination with other pharmacological and/or surgical interventions. In a particular aspect, the aptamers of the present disclosure are administered before, during, of after thrombolysis (e.g., thrombectomy) or any combination thereof. The disclosure also provides specific doses and dosage regimes.